Hepatitis, Liver Cancer and NCDs

Liver cancer can’t wait – saving lives from liver cancer by eliminating hepatitis 

Viral hepatitis is the leading cause of liver cancer, the third most common cause of cancer deaths worldwide. Yet, more than half of liver cancer cases can be prevented through screening, testing and treatment for hepatitis.  

A new report from the Centre for Disease Analysis (CDA) Foundation* finds that individuals living with hepatitis B and C have a significantly higher risk of developing cancer than someone smoking one pack of cigarettes per day.  

Despite this, nearly half (42%) of people globally are not aware that one of the leading causes of liver cancer is viral hepatitis – according to research by the World Hepatitis Alliance**.

To support advocates in their work to improve understanding of the links between hepatitis and liver cancer WHA has developed an advocacy briefing. It outlines the key facts about the connection between viral hepatitis and liver cancer and calls for greater action. This includes calling for countries to invest in hepatitis services to reduce the burden of NCDs and urging the hepatitis and cancer communities to come together to raise their collective voice to increase awareness.  

Webinar: We’re not waiting – Beating hepatitis and cancer together 

On Thursday 27 July, WHA hosted a webinar to discuss the integration of the hepatitis community and hepatitis services with liver cancer and NCDs to beat hepatitis and liver cancer together. Chaired by our director, Jessica Hicks, speakers included: 

  • Rosie Tasker, Global Advocacy Manager, Union for International Cancer Control (UICC)  
  • Devin Razavi-Shearer, Associate Director, HBV/HDV, Center for Disease Analysis Foundation  
  • Dr Nafiisah Chotun, Programme Lead, Endemic and NTDs & RISLNET Coordinator Southern African region, Africa Centres for Disease Control and Prevention (Africa CDC)  
  • Milan Mishkovikj, Director, European Liver Patients’ Assocation (ELPA)  
  • Wendy Wang, Deputy Director, Liver Disease Prevention and Treatment Research Foundation, Taiwan 

* Razavi, H. CDA Foundation, 2023. Risk of developing cancer – comparison of HBV, HCV, and smoking. DOI: 10.3252/pso.eu.EASLCONGRESS.2023 

** Global survey of 569 respondents from: Argentina, Germany, Ghana, Hong Kong, India, Nigeria, South Korea, Vietnam, and the United States of America. Participants sourced by SurveyMonkey Audience from 30 June to 4 July, 2023. Research conducted by the World Hepatitis Alliance (WHA)